Immunic

Immunic

Immunic is currently pursuing three development programs. These include:
More Details
  • the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of small molecule inhibitors of the enzyme dihydroorotate dehydrogenase, or DHODH;
  • the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated, or RORγt, an immune cell-specific isoform of RORγ;
  • and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium.

These product candidates are being developed to address diseases such as multiple sclerosis, psoriasis and gastrointestinal diseases.

https://imux.com/